Diagnosis and Management of Congestive Heart Failure
-
Upload
cardiacinfo -
Category
Documents
-
view
1.978 -
download
1
description
Transcript of Diagnosis and Management of Congestive Heart Failure
![Page 1: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/1.jpg)
Diagnosis and Management of
Congestive Heart Failure
David Putnam, MD
Albany Medical College
![Page 2: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/2.jpg)
• Coronary heart disease mortality has declined steadily since 1972
• Hospitalizations rates for CHF have increased
![Page 3: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/3.jpg)
![Page 4: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/4.jpg)
![Page 5: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/5.jpg)
Incidence of CHF
• Common medical condition that afflicts 4.8 million people in the US
• Approximately 2% of the US population has CHF
• 400,000 to 700,000 new cases per year
• Prevalence increases with age
• Up to 20 million people may have asymptomatic LV dysfunction
![Page 6: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/6.jpg)
![Page 7: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/7.jpg)
Congestive Heart Failure
• Pathophysiologic state in which cardiac output is inadequate to meet the metabolic needs of the body
• Complex clinical syndrome that can result from any cardiac disorder that impairs the ability of the ventricle to eject blood
![Page 8: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/8.jpg)
Historical Perspective of CHF
• Dropsical condition
• Central cardiac pump problem
• Circulatory dysfunction
• Disorder of renal function
• Complicated milieu of pump dysfunction, remodeling, humoral perturbation and subsequent circulatory insufficiency
![Page 9: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/9.jpg)
![Page 10: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/10.jpg)
Syndrome of CHF in the 1990s in US
• CAD most common cause ( >70% )
• Systemic and/or pulmonary congestion infrequent
• Diastolic dysfunction common in the elderly
• Sudden death frequent ( > 50% )
![Page 11: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/11.jpg)
CHF: Survival
• Average 5-year survival 50%
• Survival in women better than in men
• Risk of death is 5 to 10% annually in patients with mild symptoms
• Risk of death is 30 to 40% annually in patients with severe symptoms
![Page 12: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/12.jpg)
CHF: Survival
![Page 13: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/13.jpg)
![Page 14: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/14.jpg)
Left Ventricular Failure
• Systolic Dysfunction
• Diastolic Dysfunction
• Systolic and Diastolic Dysfunction
![Page 15: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/15.jpg)
CHF: Systolic Dysfunction
• Causative Factor
A. Loss of Muscle
B. Pressure Overload
C. Volume Overload
D. Decreased contractility
• Example
A. Myocardial Infarct
B. Hypertension
C. Valvular regurgitation
D. Dilated cardiomyopathy
![Page 16: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/16.jpg)
CHF: Diastolic Dysfunction
• Causative Factor
A. Delayed relaxation
B. Restricted filling
C. Reduced filling time
(tachycardia)
• Example
A. Ischemia
B. Hypertrophic cardiomyopathy
C. Mitral stenosis
![Page 17: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/17.jpg)
CHF: Diastolic Dysfunction
• Very common
• 20 to 40% of all new cases of CHF
• Incidence increases with age
![Page 18: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/18.jpg)
CHF: Disease Process
![Page 19: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/19.jpg)
CHF: Ventricular Dysfunction
![Page 20: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/20.jpg)
CHF: Hemodynamic Abnormalities
![Page 21: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/21.jpg)
![Page 22: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/22.jpg)
CHF: Compensatory Mechanisms
![Page 23: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/23.jpg)
CHF: Clinical PresentationCardinal Manifestations
• Dyspnea
• Fatigue
• Fluid retention ( pulmonary and peripheral edema )
![Page 24: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/24.jpg)
CHF: Steps in Evaluation
• Rule out precipitating causes
• Determine LVEF
• Systolic vs. diastolic dysfunctin
• Rule out CAD/myocardial ischemia
• Rule out significant ventricular arrhythmias
• Functional capacity
![Page 25: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/25.jpg)
CHF: Precipitating Causes
• Poor compliance with meds or diet
• Alcohol abuse
• Uncontrolled HTN
• Ischemia/MI
• Arrhythmias, e.g., atrial fibrillation
• Infection, anemia, thyrotoxicosis
• Renal dysfunction
• Medications
![Page 26: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/26.jpg)
CHF: Physical Findings
• Pulsus alternans
• Elevated jugular venous pressure
• Displaced cardiac apical impulse
• Third heart sound
• Pulmonary rales
• Hepatomegaly
• Peripheral edema
![Page 27: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/27.jpg)
CHF: Lab Tests
![Page 28: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/28.jpg)
CHF: Lab Tests
![Page 29: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/29.jpg)
Diagnosis of CHFRoutine Tests
• ECG
• Chest x-ray
• Echocardiogram
![Page 30: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/30.jpg)
CHF: ECG
![Page 31: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/31.jpg)
CHF: CXR
• Cardiomegaly
• Vascular redistribution
• Kerley B lines
• Interstitial edema
• Peri-bronchial “cuffing”
• Effusions
![Page 32: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/32.jpg)
Congestive Heart Failure
![Page 33: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/33.jpg)
CHF: Echocardiogram
• Chamber enlargement
• Wall motion abnormalities
• Diminished ejection fraction
• Possible LVH
• Possible valvular problems
• Assess diastolic dysfunction
![Page 34: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/34.jpg)
Echocardiogram
![Page 35: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/35.jpg)
Dilated Cardiomyopathy
![Page 36: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/36.jpg)
Hypertrophic Cardiomyopathy
![Page 37: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/37.jpg)
CHF: Additional Testing
• MUGA scan
• Exercise stress test
• Cardiac catheterization
• Holter monitor
![Page 38: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/38.jpg)
CHF: Treatment Goals
• Improve symptoms
A. Enhance well-being and quality of life
B. Increase exercise tolerance
• Improve survival
A. Prevent progressive heart failure
B. Prevent sudden death
C. Prevent thromboembolic episodes
![Page 39: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/39.jpg)
CHF: Medical Management
• Diuretics
• Digitalis
• ACE Inhibitors
• Beta Blockers
• Spironolactone
![Page 40: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/40.jpg)
CHF: Diuretics
• Reduce volume overload
• Reduce sodium overload
• Preload reduction
![Page 41: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/41.jpg)
CHF: Diuretics
Advantages
• Highly effective in most classes
• Essential with fluid retention
• Well tolerated, simple to use
Disadvantages
• Electrolyte abnormalities
• Hypovolemia, hypotension, renal dysfunction
• Activation of neurohormaonal system
![Page 42: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/42.jpg)
CHF: Diuretics
• Elimination of symptoms and/or signs of congestion
• Avoid volume depletion
A. Postural hypotension
B. Increase in heart rate
C. Increase in BUN/Cr
D. Neuroendocrine activation
![Page 43: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/43.jpg)
Diuretics
Thiazide Diuretics
• HCTZ
• Chlorthalidone
• Metolazone
Loop Diuretics
• Furosemide
• Torsemide
Potassium Sparing Diuretics
• Spironolactone
• Triamterene
• Amiloride
![Page 44: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/44.jpg)
CHF: SpironolactoneRALES Study
• Spironolactone 25 mg/day in Class III or IV patients in addition to ACE and loop diuretics
• 30% reduction in mortality
• 31% reduction in cardiac mortality
• Anti-aldosterone effect
Pitt B. NEJM 1999;341:709-717
![Page 45: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/45.jpg)
CHF: Digoxin
• Improves rest and exercise hemodynamics
• Attenuates neurohormal abnormalities
• Improves symptoms
• May result in fewer hospitalizations and ER visits
• Has unknown effects on mortality
![Page 46: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/46.jpg)
CHF: Digoxin
• Useful in patients with CHF and supraventricular arrhythmias
• Useful in patients with systolic dysfunction
• Disadvantages include:
A. Narrow Rx range
B. Synergistic toxicity with hypokalemia
C. Drug interactions
D. Possible arrhythmogenesis
![Page 47: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/47.jpg)
CHF: ACE Inhibitors
• Improve hemodynamic status
• Attenuate neurohumoral abnormalities
• Improve symptoms
• Reduce incidence of hospitization
• Slow progression
• Reduce mortality
![Page 48: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/48.jpg)
CHF: ACE Inhibitors
Neurohormonal Changes
• Decreased angiotensin II
• Increased bradykinin
• Decreased or no change in aldosterone
• Decreased norepinephrine
![Page 49: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/49.jpg)
CHF: ACE Inhibitors
Reduction in Sudden Death/Potential Mechanisms
• Increase in serum/total body potassium
• Decreased adrenergic stimulation
• Reduced heart size and decrease in ventricular hypertrophy
• Prevention of myocardial ischemia
• Prevention of progressive myocardial damage
![Page 50: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/50.jpg)
CHF: FDA Approved ACE Inhibitors
• Captopril
• Enalapril
• Lisinopril
• Quinapril
• Trandolapril
• Fosinopril
![Page 51: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/51.jpg)
CHF: ACE Inhibitor Doseages
Captopril
Enalapril
Lisinipril
Quinapril
• Start: 6.25 bid/tid
• Usual: 6.25-50 bid/tid
• Start: 2.5 qd/bid
• Usual: 2.5-10 bid
• Start: 2.5-5 qd
• Usual: 5-20 qd
• Start: 5 bid
• Usual 10-20 bid
![Page 52: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/52.jpg)
ELITE IIELITE II Primary Endpoint: All-Cause MortalityPrimary Endpoint: All-Cause Mortality
00 100100 200200 300300 400400 500500 600600 700700
Days of Follow-upDays of Follow-up
0.00.0
0.20.2
0.40.4
0.60.6
0.80.8
1.01.0
Pro
babi
lity
of S
urvi
val
Pro
babi
lity
of S
urvi
val
LosartanLosartanCaptopril Captopril
Hazard Ratio (95-7% C.I.) = 1.13 (0.95-1.35) P = 0.16Hazard Ratio (95-7% C.I.) = 1.13 (0.95-1.35) P = 0.16
Lancet Lancet 2000;355:1582-872000;355:1582-87
![Page 53: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/53.jpg)
ELITE IIELITE IIWithdrawal for Adverse Experience (Excluding Death)Withdrawal for Adverse Experience (Excluding Death)
0
5
10
15
20
Any AE Drug-RelatedAE
Cough HF
% o
f P
atie
nts
Losartan (N=1578)Captopril (N=1574)
******** p p0.001 between 0.001 between groupsgroups
****
****
Lancet Lancet 2000;355:1582-872000;355:1582-87
![Page 54: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/54.jpg)
ELITE IIELITE IIDiscussionDiscussion
• Losartan was not superior to captopril in improving survival in elderly heart-failure patients, but was significantly better tolerated.
• Based on extensive randomized, placebo-controlled observations, ACE inhibitors should be the initial treatment for heart failure, although angiotensin II receptor antagonists may be useful to block the renin angiotensin aldosterone system when ACE inhibitors are not tolerated.
Lancet Lancet 2000;355:1582-872000;355:1582-87
![Page 55: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/55.jpg)
CHF: Beta Blockers
• Acutely depresses myocardial function (pharmacological)
• Chronically improves myocardial function (biological)
![Page 56: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/56.jpg)
CHF: Beta Blockers
• Primary mechanism is inhibition of down regulation of beta receptors
• Additional mechanismsA. Restore receptor densityB. Protect against cardiotoxicity of
catecholeaminesC. Improve systolic/diastolic function in
ischemic myocardium
![Page 57: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/57.jpg)
Beta Blockers
• First Generation: Beta 1 and Beta 2
Propranolol/Timolol
• Second Generation: Beta 1
Metoprolol/Atenolol
• Third Generation: Vasodilating Properties
Carvedilol
![Page 58: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/58.jpg)
CHF: Beta Blockers
Improve symptoms and clinical class
• Degree of benefit appears to relate to degree of disability before treatment
Reduce Mortality
• 5 trials with metoprolol/bisoprolol
• 5 trials with carvedilol
![Page 59: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/59.jpg)
CHF: Metoprolol vs. Carvedilol
• Randomized, double-blind comparison
• 150 patients followed for 12 months
• Class II, III, IV
• LVEF <=35%
• Greater improvement in cardiac function with Carvedilol
Circulation 2000(AUG);102:546-551.
![Page 60: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/60.jpg)
CHF: Beta Blockers
• Should be used in all stable Class II/III patients unless contraindicated
• Treatment should not be initiated in patients with acutely decompensated CHF
• Clinical response may take 2 to 3 months
![Page 61: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/61.jpg)
CHF: Beta Blockers
Risks of Treatment
• Hypotension
• Fluid retention and worsening CHF
• Bradycardia and heart block
![Page 62: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/62.jpg)
CHF: Beta Blockers
• Carvedilol
• Metoprolol
• Bisoprolol
• Start: 3.125 mg bid
• Usual: 25 mg bid
• Start: 12.5-25 mg qd
• Usual: 50-100 mg bid
• Start: 1.25 mg qd
• Usual: 5-10 mg qd
![Page 63: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/63.jpg)
CHF: IV Dobutamine
• 80 patients with class III/IV CHF
• Continuous IV Dobutamine @ 9 mcg/kg/min for 14 days
• Adverse event rate in treatment group: 85%
• Adverse event rate in placebo group: 65%
AM HRT J 1999;138:78-86
![Page 64: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/64.jpg)
CHF: IV Dobutamine
• Continuous IV Dobutamine has never been shown to improve survivorship
• Intermittent infusion has been called into question
Ewy GA. JACC 1999;33:572-74
![Page 65: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/65.jpg)
CHF: Diastolic Dysfunction
• Difficult to treat
• Diuretics for volume overload. Avoid volume depletion
• Prevent tachycardia
• Rate-limiting calcium channel blockers first choice
• Beta 1 beta blockers second choice
![Page 66: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/66.jpg)
Diastolic Time and Heart Rate
![Page 67: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/67.jpg)
CHF: Diastolic Dysfunction
Benefits of Calcium Channel Blockers
• Slowing of heart rate
• Reduction of MVO2
• Control of BP
• Regression of LVH
• Dilation of coronary microcirculation
• Amelioration of intracellular calcium overload
![Page 68: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/68.jpg)
CHF: Diastolic Dysfunction
Benefits of Beta Blockers
• Slowing of heart rate
• Reduction of MVO2
• Control of blood pressure
• Regression of LVH
![Page 69: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/69.jpg)
CHF: Treatment Scheme
![Page 70: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/70.jpg)
The End
![Page 71: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/71.jpg)
Myocardial Oxygen Consumption
![Page 72: Diagnosis and Management of Congestive Heart Failure](https://reader033.fdocuments.in/reader033/viewer/2022061112/545997bcb1af9f33608b5538/html5/thumbnails/72.jpg)
CHF: ACE Inhibitors
• 18 patients with SBP 60 to 100
• At four weeks 82% of patients were tolerating Lisinipril 40 mg/day